Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

The Lancet

Volumn 371, Issue 9625, 2008, Pages 1675-1684

  Papp, Kim A ^a   Langley, Richard G ^b   Lebwohl, Mark ^c   Krueger, Gerald G ^d   Szapary, Philippe ^e   Yeilding, Newman ^e   Guzzo, Cynthia ^e   Hsu, Ming Chun ^e   Wang, Yuhua ^e   Li, Shu ^e   Dooley, Lisa T ^e   Reich, Kristian ^f  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e CENTOCOR INC   (United States)

^f Dermatologikum Hamburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 23; MONOCLONAL ANTIBODY; PLACEBO; USTEKINUMAB;

ADULT; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; BODY SURFACE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEMYELINATING DISEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEOPLASM; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SERUM SICKNESS; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 43449139402     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60726-6     Document Type: Article

References (21)

1. JG Krueger A Bowcock Psoriasis pathophysiology: current concepts of pathogenesis Ann Rheum Dis 64 suppl 2 2005 ii30 ii36
2. MA Lowes AM Bowcock JG Krueger Pathogenesis and therapy of psoriasis Nature 445 2007 866 873
3. J Koo Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment Dermatol Clin 14 1996 485 496
4. MP Schon WH Boehncke Psoriasis N Engl J Med 352 2005 1899 1912
5. GG Krueger RG Langley C Leonardi A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis N Engl J Med 356 2007 580 592
6. AB Kimball KB Gordon RG Langley Safety and efficacy of ABT-874, a fully human interleukin-12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial Arch Dermatol 144 2008 200 207
7. C Leonardi AB Kimball K Papp Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 2008 1165 1174
8. Gottlieb A, Menter A, Mendelsohn A, et al. Phase II, randomized, placebo-controlled study of ustekinumab, a human interleukin-12/23 monoclonal antibody, in psoriatic arthritis. American College of Rheumatology Annual Meeting; Boston, MA, USA; Nov 6–11, 2007.
9. JR Chan W Blumenschein E Murphy IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis J Exp Med 203 2006 2577 2587
10. K Hong A Chu BR Ludviksson EL Berg RO Ehrhardt IL-12, independently of IFN-γ, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder J Immunol 162 1999 7480 7491
11. AB Gottlieb KD Cooper TS McCormick A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis Curr Med Res Opin 23 2007 1081 1092
12. CL Kauffman N Aria E Toichi A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis J Invest Dermatol 123 2004 1037 1044
13. CS Carlin SR Feldman JG Krueger A Menter GG Krueger A 50% reduction in the psoriasis area and severity index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis J Am Acad Dermatol 50 2004 859 866
14. SJ Pocock R Simon Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial Biometrics 31 1975 103 115
15. T Fredriksson U Pettersson Severe psoriasis—oral therapy with a new retinoid Dermatologica 157 1978 238 244
16. AY Finlay GK Khan Dermatology life quality index (DLQI)—a simple practical measure for routine clinical use Clin Exp Dermatol 19 1994 210 216
17. D Geng G Shankar A Schantz M Rajadhyaksha H Davis C Wagner Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies J Pharm Biomed Anal 39 2005 364 375
18. AL Neimann DB Shin X Wang DJ Margolis AB Troxel JM Gelfand Prevalence of cardiovascular risk factors in patients with psoriasis J Am Acad Dermatol 55 2006 829 835
19. JM Gelfand AL Neimann DB Shin Risk of myocardial infarction in patients with psoriasis JAMA 296 2006 1735 1741
20. HL Richards DG Fortune CE Griffiths Adherence to treatment in patients with psoriasis J Eur Acad Dermatol Venereol 20 2006 370 379
21. SS Zaghloul MJD Goodfield Objective assessment of compliance with psoriasis treatment Arch Dermatol 140 2004 408 414